INM.WAR InventionMed
- Market cap
- PLN 22.4M
- P/E
- -
- P/B
- 17.76x
- ROE
- 76.0%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is INM.WAR undervalued?
Graham numberThe Graham number of InventionMed cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
InventionMed fundamental analysis
4 of 22 checks passedROE 2/2
High return on equity (76.0%), above 20%.
ROA 1/1
Return on assets (2.3%) is above the industry median (-6.0%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (83.0%) is above the industry median (24.1%).
Revenue Growth 2/2
Revenue grew 820.5% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 0/1
EBIT is 1.7x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (17.8x) is above the industry median (3.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
InventionMed stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About InventionMed
InventionMed S.A. focuses on the development of medical simulators based on Virtual Realty technology for use in education in esthetic and clinical dermatology. The company flagship project is TutorDerm, a simulator and an application that lets users perform actions necessary to treat specific dermatological diseases. It also offers double immersion, and Virtual Syringe, a training equipment for specialists in clinical and aesthetic dermatology. In addition, the company prov…
Full company profileInventionMed financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
InventionMed annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 850K | - | 41.0K | 5.20K | 10.5K | 4.07K | 300.00 | 278K | 3.17M | 3.00M |
| Gross Profit | - | - | 258.60 | 43.50 | 1.08 | 5.25K | -2.39K | -10.3K | 97.6K | 2.91M | 2.89M |
| Operating Income | -446K | 348K | -1.13M | -886K | -548K | -674K | -755K | -1.17M | -2.47M | 818K | 2.29M |
| EBITDA | - | - | 851.20 | 1.37 | 1.08 | 1.11 | -21.8M | 34.1K | -2.02M | 1.74M | 3.18M |
| Net Income | -408K | 302K | -1.19M | -770K | -428K | -674K | -22.2M | -1.89M | -4.41M | -749K | 950K |
| EPS | - | - | - | - | 0.00 | 0.00 | -0.11 | -0.01 | -0.02 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | - | - | 14.0M | 13.3M | 32.1M | 43.7M | 30.4M | 42.9M | 37.9M | 39.5M | 40.4M |
| Total Liabilities | - | - | 158K | 667K | 1.46M | 13.7M | 22.5M | 37.0M | 36.4M | 38.7M | 39.2M |
| Shareholders' Equity | - | - | 13.8M | 12.7M | 30.6M | 30.0M | 7.82M | 5.93M | 1.52M | 775K | 1.25M |
| Cash & Short-term Investments | 8.50M | - | 3.30M | 12.3M | 687K | 5.68M | 3.95M | 5.22K | 3.05K | 103K | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -244K | 566K | -920K | -654K | -1.49M | 7.54M | 1.76M | 419K | 831K | -498K | -290K |
| Capital Expenditure | 132K | 0.00 | 0.00 | 88.8K | 3.42M | 3.00M | 8.12M | 15.3M | 135K | 582K | 0.00 |
| Free Cash Flow | - | - | - | - | -4.91M | 4.54M | -6.36M | -14.9M | 696K | -1.08M | -290K |
| Ratios | |||||||||||
| ROE | - | - | -8.6% | -6.1% | -1.4% | -2.2% | -283.3% | -31.9% | -288.9% | -96.6% | 76.0% |
| ROA | - | - | -8.5% | -5.8% | -1.3% | -1.5% | -73.0% | -4.4% | -11.6% | -1.9% | 2.3% |
| Net Profit Margin | - | 35.5% | - | -1,879.2% | -8,231.7% | -6,450.4% | -544,997.3% | -629,721.6% | -1,586.1% | -23.6% | 31.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
InventionMed dividends
InventionMed has not paid dividends in the last 9 fiscal years.
Last stock split: 4:1 on Sep 6, 2022.
Who owns InventionMed
- Insiders 43.90%
- Institutions 0.00%
- Public & others 56.10%
- Shares outstanding 203M
- Free float 114M
InventionMed company profile
- Company name
- InventionMed
- Ticker
- INM.WAR
- ISIN
- PLCDE0000010
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5
- Fiscal year end
- December
- Address
- Jana Zamoyskiego 2B Street, Bydgoszcz, Poland, 85-063
- Phone
- 48 52 340 5030
- Website
- inventionmed.com
About InventionMed
InventionMed S.A. focuses on the development of medical simulators based on Virtual Realty technology for use in education in esthetic and clinical dermatology. The company flagship project is TutorDerm, a simulator and an application that lets users perform actions necessary to treat specific dermatological diseases. It also offers double immersion, and Virtual Syringe, a training equipment for specialists in clinical and aesthetic dermatology. In addition, the company provides education and training services, as well as simulators of medical equipment. The company was incorporated in 2012 and is based in Bydgoszcz, Poland.
InventionMed management
2- Mr. Tomasz KierulPresident of Management Board & CEO
- Marcin Janusz HauffaMember of the Management Board